Novartis said Friday it has pulled its irritable bowel treatment Zelnorm (tegaserod maleate) off the US market after new clinical data showed an increased risk of cardiovascular events in patients ...
ZURICH, March 30 (Reuters) - Novartis pulled bowel drug Zelnorm from U.S. shelves on Friday at the request of regulators because clinical trial data indicated a possible link to heart attacks and ...
ZURICH, March 30 (Reuters) - Novartis AG has pulled its bowel drug Zelnorm from the U.S. market at the request of regulators, after clinical trial data indicated a link to heart attacks and stroke.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback